PureTech

We're a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value for patients and shareholders

[PureTech @PureTechH]

We have built a model designed to repeatedly create, advance, & fund innovative therapeutic programs - an approach that has contributed to 3 FDA approvals & the creation of multiple Founded Entities (Seaport Therapeutics, Celea Therapeutics, Gallop Oncology, & more)

Our CEO Rob Lyne and President & Co-Founder Eric Elenko recently joined the Base to Base Biotech podcast to discuss the evolution of that model, recent portfolio progress, and the many catalysts ahead.

Listen here: https://t.co/5o8EDQ4C0f
PureTech interview begins at 31:56

[PureTech @PureTechH]

Join us at #ATS2026! We’ll detail SURPASS-IPF (first industry-sponsored, head-to-head, Ph3 superiority #IPF trial) & insights on the translatability of our Ph2b data. So proud of our Celea colleagues who are advancing deupirfenidone as a potential new SOC https://t.co/jXPHr6296o

[PureTech @PureTechH]

Today we announced our 2025 Full Year Results and Annual Report, highlighting continued progress across our Portfolio with a sharpened strategic focus on disciplined capital allocation, operational efficiency, & long-term value creation.

Join us at 9AM EDT/2PM BST as we discuss how PureTech is positioned for the future https://t.co/lgVHZaB3HP

[PureTech @PureTechH]

We’re pleased to share positive topline data from Ph1b trial of LYT-200 in relapsed/refractory (R/R) high-risk #MyelodysplasticSyndrome & R/R #AcuteMyeloidLeukemia. Our Founded Entity, Gallop Oncology, intends to discuss next steps w/ FDA in R/R HR-MDS. https://t.co/yGKToot65u

[PureTech @PureTechH]

Now published in @ATSBlueEditor: full results from the Phase 2b ELEVATE IPF trial of deupirfenidone

These results provide a strong scientific & clinical foundation as our Founded Entity, Celea Therapeutics, prepares to advance deupirfenidone into Phase 3. https://t.co/lJ4N3rXKGz

#idiopathicpulmonaryfibrosis #ipf

[PureTech @PureTechH]

Today our Founded Entity @SeaportTx announced the publication of a manuscript that captures the discovery process behind the creation of GlyphAllo, further validating the Glyph platform.

Initially advanced at PureTech, GlyphAllo is a hallmark of our strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation.

[SeaportTx @SeaportTx]

New paper in @ScienceTM features GlyphAllo as first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans & further validates Glyph platform to effectively enable oral dosing.

Paper: https://t.co/S2hv2RymXc
Release: https://t.co/SVAz6aJfjs

[PureTech @PureTechH]

On #RareDiseaseDay, the world recognizes & supports those living w/ #rarediseases. At PureTech, this is our focus every day.

Today, our team joined @Cycle4Survival to champion rare cancer research – an extension of our work at Gallop Oncology to advance LYT-200 in #AML.

The same commitment drives our team at Celea Therapeutics to advance deupirfenidone for pp w/ #IPF.

Both programs received Orphan Drug Designation, reflecting the need in these communities & what drives us to deliver on our mission .

[PureTech @PureTechH]

Our CEO, Robert Lyne, and Co-founder & President, Eric Elenko, PhD, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT.
https://t.co/pVbdnP66g5

[PureTech @PureTechH]

During #RareDiseaseMonth, we’re reminded that innovation matters most where options are few.

Today we're proud to share that deupirfenidone has received #OrphanDrugDesignation from the FDA and European Commission for #IPF.

Read More: https://t.co/ziM3UvtY7z

[PureTech @PureTechH]

On #InternationalDayofWomenandGirlsInScience, we’re proud to recognize the women shaping the future of PureTech.

From advancing new possibilities in #IPF & #AML, to translating ideas into medicines, they exemplify scientific leadership.

By amplifying their voices today, we aim to inspire the next gen of #WomenInSTEM

#IDWGS

[PureTech @PureTechH]

Our CEO, Robert Lyne, and President, Eric Elenko, presented at #JPM26, outlining PureTech’s strategy, portfolio progress, and priorities for the year ahead. Watch the presentation replay here: https://t.co/g9tDmM0OBL

[PureTech @PureTechH]

Our CEO, Robert Lyne, will present at #JPM26 on Wednesday, January 14th, at 4:30pm PST / 7:30pm EST https://t.co/aC5m2DdqnW

[PureTech @PureTechH]

Wishing our colleagues, shareholders, and the patients we serve a warm and joyful holiday season. We look forward to continuing our important work together in 2026!

[PureTech @PureTechH]

Today we announced the appointment of Robert Lyne as CEO.

Rob brings deep familiarity with our programs, people, and model, and will lead PureTech in building on this strong foundation to advance transformative therapies for patients and create value for shareholders https://t.co/Z02y9elzHR

[PureTech @PureTechH]

Today we announced the successful completion of the End-of-Ph2 meeting w/ FDA for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis #IPF. The Ph3 SURPASS-IPF trial is on track to start in 1H26 by our newest Founded Entity, Celea Therapeutics. https://t.co/uxHGZ92SuW

[PureTech @PureTechH]

We’re proud to share positive initial topline data from the Ph1b trial of LYT-200 in relapsed/refractory #AML & high-risk #MDS. Our Founded Entity, Gallop Oncology, will present additional details tomorrow at #ASH25 https://t.co/AGFyR3cKjq

[PureTech @PureTechH]

Happy Thanksgiving from all of us at PureTech!

[PureTech @PureTechH]

New data from our Phase 1b trial of LYT-200 in #AML will be presented at #ASH25. Results to date show strong clinical activity + favorable safety in heavily pretreated patients. Matured data to come at ASH & in Q4 2025 https://t.co/DAUgzCLfFN